News file for: Eisai Group

Otsuka Acquires Leukemia Drug Dacogen® From Eisai

Otsuka Acquires Leukemia Drug Dacogen® From Eisai

Otsuka Pharmaceutical acquires two drugs, Dacogen® and E7727, from Eisai Co. to enhance their leukemia drug portfolio.

US$12 Million In Grants Awarded For Neglected Diseases

US$12 Million In Grants Awarded For Neglected Diseases

Japan’s Global Health Initiative Technology Fund has committed US$12 million in grants for neglected diseases and a potential tuberculosis vaccine.

Eisai, Broad Institute Develop Treatment For NTDs And Tuberculosis

Eisai, Broad Institute Develop Treatment For NTDs And Tuberculosis

Eisai Co., Ltd. has entered into an agreement with the Broad Institute to develop new therapeutic agents for the treatment of neglected tropical diseases and tuberculosis. 



Japan Launches Public-Private Partnership To Fight Neglected Diseases

Japan Launches Public-Private Partnership To Fight Neglected Diseases

The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.

Eisai Receives Russian Approval For Anti-Epileptic Drug, Zonegran

Eisai Receives Russian Approval For Anti-Epileptic Drug, Zonegran

Eisai Co. Ltd. announced today that it has received Russian regulatory approval for its antiepileptic drug, Zonegran (zonisamide).

Coalition Aims To Eradicate 10 Neglected Tropical Diseases By 2020

Coalition Aims To Eradicate 10 Neglected Tropical Diseases By 2020

A large coalition of pharmas, governments, and NGOs have announced their goal of eliminating or controlling 10 neglected tropical diseases by 2020.

IBM Opens New Branch Office In Visakhapatnam, India

IBM Opens New Branch Office In Visakhapatnam, India

IBM has opened a branch office in Visakhapatnam, Southeast India as part of the company’s continued geographic expansion initiative to increase its presence in key growth markets.